Elexacaftor/tezacaftor/ivacaftor in children aged ≥6 years with cystic fibrosis heterozygous for F508del and a minimal function mutation: results from a 96-week open-label extension study - Mall, MA; Wainwright, CE; Legg, J; Chilvers, M; Gartner, S; Dittrich, A-M; Stehling, F; Conner, S; Grant, S; Suresh, N; Weinstock, TG; Davies, JC (EUROPEAN RESPIRATORY JOURNAL, 2025)